Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Samuel Pruden

MOHS-Micrographic Surgery Lexington, KY Medical Doctor

NPI 1871593996 CMS profile 701883

989 Governors Ln Ste 260, Lexington, KY 40513

Open in the dashboard

General payments

$1,354

78 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Samuel Pruden of Lexington, KY is reported in the CMS Open Payments database as having received $1,354 across 78 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 44th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $35 2
2022 General $142 7
2021 General $507 22
2020 General $282 17
2019 General $388 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samuel Pruden
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Samuel Pruden were reported at $35. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Samuel Pruden MOHS-Micrographic Surgery median Middle half National median
2019 $388 $316 $106–$785 $163
2020 $282 $162 $68–$412 $114
2021 $507 $243 $87–$654 $132
2022 $142 $300 $102–$887 $149
2023 $0 $364 $125–$1,010 $160
2024 $0 $445 $142–$1,108 $164
2025 $35 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $463 27 payments
  2. Pfizer Inc. $200 18 payments
  3. Genentech USA, Inc. $121 7 payments
  4. Sensus Healthcare, Inc. $97 1 payment
  5. Regeneron Healthcare Solutions, Inc. $83 4 payments
  6. Janssen Biotech, Inc. $79 4 payments
  7. UCB, Inc. $77 4 payments
  8. Genzyme Corporation $69 3 payments
  9. Novartis Pharmaceuticals Corporation $56 3 payments
  10. DUSA Pharmaceuticals, Inc. $31 2 payments
  11. Other $78 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,354 78 payments
Products named General payments · program years 2019–2025
  1. HUMIRA $399 21 payments
  2. SKYRIZI $235 17 payments
  3. EUCRISA $200 18 payments
  4. Erivedge $121 7 payments
  5. LIBTAYO $88 4 payments
  6. Cimzia $77 4 payments
  7. COSENTYX $56 3 payments
  8. SIMPONI $54 3 payments
  9. SIMPONI ARIA $54 3 payments
  10. STELARA $54 3 payments
  11. Other $291 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

335

Median for Dermatology: 534

Drug cost

$166,791

Median for Dermatology: $67,151

Branded share of claims

19.4%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Erivedge Vismodegib Brand 11 $160,705
Fluorouracil Generic 28 $2,219
Hydroxychloroquine Sulfate Generic 24 $836
Fluocinonide Generic 22 $672
Triamcinolone Acetonide Generic 33 $609
Clobetasol Propionate Generic 15 $547
Minocycline Hcl Generic 44 $376
Doxycycline Monohydrate Generic 17 $290
Doxycycline Hyclate Generic 32 $287
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 54 $151

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 84 billing codes

Paid by Medicare

$296,387

Of which drugs: $15,517

Medicare patients

235

Average age 74

Services billed

13,171

101 women, 134 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 41%
Diabetes 26%
Ischemic heart disease 18%
Atrial fibrillation 18%
Chronic kidney disease 18%
COPD 16%
Depression 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 34 10,200 $13,577

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

78 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record